Silo Pharma Inc. (NASDAQ: SILO) announced a strategic expansion into artificial intelligence as a second line of business following its acquisition of assets from Qwikagents.ai, a platform designed to deploy autonomous AI agents for tasks including research, content generation, scheduling and workflow automation. The move positions the company to capitalize on a rapidly growing AI agent market projected to reach $47 billion to $53 billion by 2030, according to the press release.
While expanding into AI, Silo Pharma continues advancing its SPC-15 PTSD program toward an investigational new drug application submission and Phase 1 clinical trials, underscoring a dual focus on biopharmaceutical development and emerging AI-driven revenue opportunities. The company's therapeutic focus includes stress-induced psychiatric disorders, chronic pain, and central nervous system diseases, with a portfolio including SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis.
This acquisition signals a significant shift for Silo Pharma, which has historically been a biopharmaceutical and cryptocurrency treasury company. By entering the AI agent space, the company diversifies its revenue streams and taps into a market that analysts project will grow substantially over the next decade. The AI agent market encompasses autonomous software that can perform complex tasks without human intervention, offering efficiency gains across industries.
The full press release is available at this link. For the latest news and updates on Silo Pharma, visit the company's newsroom at https://ibn.fm/SILO.
The implications of this announcement are twofold. First, it highlights the growing convergence of biotech and AI, as companies seek to leverage technology to accelerate drug development and operational efficiency. Second, it underscores the importance of diversification for developmental-stage biopharmaceutical firms, which often face long timelines and high costs in bringing drugs to market. By adding an AI revenue stream, Silo Pharma may reduce its reliance on future drug approvals and generate near-term income.
For the industry, this move could signal a trend where biotech companies adopt AI as a secondary business to fund primary research. For investors, it introduces both opportunity and risk, as the success of the AI venture depends on market adoption and execution. The projected market size of $47-$53 billion by 2030 suggests significant potential, but competition in the AI agent space is intense, with many startups and tech giants vying for market share.
As Silo Pharma pursues its dual strategy, the company will need to balance resource allocation between its biopharmaceutical pipeline and AI operations. The outcome could provide a blueprint for other small-cap biotech firms seeking to broaden their revenue base without diluting their core mission.
